News : Vaccine

View:
 

Found press releases

 

Lower incidence of genital warts in young girls

3/14/2013 2:15 AM EST  -   Karolinska Institutet
The incidence of genital warts, or condylomata, declined by 93 per cent in girls given the HPV vaccine before the age of 14, according to a Swedish national registry study. The study was carried out by researchers at Karolinska Institutet in Sweden, and published in the Journal of the National Cancer Institute.
Using a selection of population-based registries, the researchers at Karolinska Institutet studied...

IBC Urges Members to Get a Flu Shot

1/10/2013 3:25 PM EST  -   Independence Blue Cross
Top Five Reasons Why It’s Not Too Late
Philadelphia, PA, January 10, 2013 – It’s the height of flu season, and it probably seems as though everyone around you is coming down with the flu. Still, it’s not too late to protect yourself, family, and friends from this serious illness. Independence Blue Cross (IBC) is urging its members to get their flu shots and offering ways to avoid getting sick.  

“Although most...

UT Arlington receives Grand Challenges Explorations grant for groundbreaking res...

1/10/2013 12:55 PM EST  -   University of Texas at Arlington
Two UT Arlington engineers will use a new Bill & Melinda Gates Foundation grant to update an ancient method of evaporation to cool vaccines and medicine that must be shipped to remote parts of the world without ready access to electricity.

The University of Texas at Arlington announced that it is a Grand Challenges Explorations winner, an...

Genetic Immunity Clinical Trial Data Published in Plos One

5/17/2012 10:00 AM EST  -   Genetic Immunity
Genetic Immunity Clinical Trial Data Published in Plos OneDermaVir Immunization Boosted Long-lasting Memory T-cell Responses in Every Patient
McLean, VA and Budapest, Hungary, May 17, 2102 – Genetic Immunity Inc., a privately-held, biopharmaceutical company developing Langerhans cell-targeted immunotherapies, published its human proof-of-concept clinical trial, in PLoS ONE, a...

California’s First and Only Center for the Promotion of Maternal Health and Infa...

5/3/2012 7:27 AM EST  -   MotherToBaby, a service of the Organization of Teratology Information Specialists (OTIS)
Center Houses Groundbreaking Fetal Health Research Projects
For Immediate Release 5/3/2012

SAN DIEGO, CA- Two University of California, San Diego professors who run a statewide pregnancy health information service as well as conduct fetal health research, will unveil the Center for the Promotion of Maternal Health and Infant Development on May 3rd during a grand opening celebration and symposium. The new...

VISCOGEL INITIATES PHASE I/II CLINICAL TRIAL FOR ITS NOVEL VACCINE ADJUVANT

4/23/2012 5:42 AM EST  -   Viscogel AB
Viscogel AB today announced that dosing began in the Phase I/II clinical trial with ViscoGel®, a novel vaccine adjuvant based on the company's proprietary chitosan technology. ViscoGel® has been shown to be safe and effective in pre-clinical studies.
The first part of the Phase I/II trial is a single-ascending dose study with ViscoGel® in 30 healthy volunteers. The second part is a single-dose study in 100...

VISCOGEL AB REPORTS POSITIVE RESULTS FROM SAFETY STUDIES

2/27/2012 10:26 AM EST  -   Viscogel AB
Viscogel AB today announced a successful completion of the toxicology studies that were carried out within the ViVac-project. The results showed that ViscoGel® was well tolerated even at higher doses and no unexpected effects were observed.
The recent toxicology studies were completed in order to prepare for the planned clinical trial with the company’s vaccine adjuvant, ViscoGel®. The toxicology results were...

Vaccine market has soared to over $27 billion says new report

2/9/2012 11:23 AM EST  -   Reportbuyer
Piribo, the online destination for Pharma intelligence, has added a new report.
According to the report “Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts)” available at ten years ago the vaccine market was $5.7...

Results on ViscoGel® adjuvant published in Vaccine

12/19/2011 4:46 AM EST  -   Viscogel AB
Preclinical results describing the efficacy of ViscoGel® - a novel vaccine adjuvant - were recently published in the peer-reviewed journal Vaccine.  The results support Proof of Concept for ViscoGel® as an effective vaccine adjuvant.
In the published preclinical studies, ViscoGel® was used as an adjuvant together with Act-HIB®, a commercial vaccine against Haemophilus influenzae. ViscoGel® significantly...
Senior Medical Director of Prescription Drug Plans, Pharmacy and Health Services
 

Diabetes and the Flu

12/22/2010 12:57 PM EST  -   WellCare Health Plans Inc.
By: Dr. Alan Smith
Senior Medical Director of Prescription Drug Plans, Pharmacy and Health Services, WellCare Health Plans, Inc.
During each annual flu season, campaigns are launched to convince as many people as possible to get the seasonal flu vaccine. The Centers for Disease Control and Prevention (CDC) annually highlights high-risk populations and urges these people to get vaccinated as soon as possible....